Home > Boards > US OTC > Medical - Healthcare > AngioSoma Inc. (SOAN)


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
centsability4me Member Profile
Member Level 
Followed By 34
Posts 2,997
Boards Moderated 3
Alias Born 06/17/13
160x600 placeholder
centsability4me Member Level  Wednesday, 08/14/19 07:51:04 AM
Re: None
Post # of 8247 

AngioSoma - Our Science Comes From The Heart


AngioSoma is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD). AngioSoma is developing its lead product, a drug candidate called LiprostinTM for the treatment of peripheral artery disease, or PAD, which has completed FDA Phase I and three Phase II clinical trials.

Our innovative supplements cover three industry segments:

Nutraceuticals, Cosmeceuticals, and Pharmaceuticals



Transdermal PGE - 1 Patch

OMNICATH 1 & OMNICATH 2 - Atherectomy Devices


Men's Stem Strength™ Deluxe AM

Men's Stem Strength™ Deluxe PM

Women's Stem Strength™ Deluxe AM

Women's Stem Strength™ Deluxe PM

Men’s StemStrength – Workout Amplifier


Rapid Wrinkle Reducer™


Powerful Peptide Eye Serum™

Collagen Anti-Aging Crème™


Products in Development


Somniac PM™


AngioSoma Launches E-Commerce Website


HOUSTON, TX, April 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC:SOAN), a leading developer of dietary supplements and biotechnology research and development company, is pleased to announce the launch of its long awaited e-commerce website: www.soma-ceuticals.com.

Our website will emphasize our workout amplifier, StemStrength Deluxe AM and PM for men and women. The website also offers beauty products including Anti-Aging Crème, Eye Serum and Anti-Wrinkle Serum.

"We are excited about our new website," said Alex Blankenship, President of AngioSoma. "The greater visibility for offering our supplements for sale to the public is a substantial step forward."

AngioSoma is moving forward with the pending combination with Diabetes Relief that will complement the treatment of peripheral neuropathy along with our patented drug, Liprostin. The Company is continuing to explore opportunities to move forward with the final clinical trials to receive FDA approval.

Lower extremity peripheral artery disease is the third leading cause of death from hardening of the arteries to the heart (atherosclerotic cardiovascular morbidity), following coronary artery disease and stroke.

More than 20 million people in the United States have been estimated to have some form of peripheral neuropathy, but this figure may be significantly higher—not all people with symptoms of neuropathy are tested for the disease and tests currently don't look for all forms of neuropathy. Neuropathy is often misdiagnosed due to its complex array of symptoms.

Diabetes Relief's Programs Can Reduce Costs to Insurance Payers


HOUSTON, TEXAS, April 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – AngioSoma, Inc. (OTC: SOAN) is concerned that economic costs of diabetes in the USA were $327 BILLION in 2017, as reported by the American Diabetes Association. Of that total, $98 BILLION was spent on diabetic hospital admissions and $10.9 BILLION on diabetic neuropathy alone. Diabetes Relief’s patients report marked improvement in neuropathy as well as fewer hospitalizations, and testimonials are available at www.diabetesrelief.com. With economic costs of diabetes in the USA expected to rise to $622 BILLION by 2030, AngioSoma believes that increased availability of Diabetes Relief’s treatment will help reduce the impact of diabetic complications on insurance companies.

AngioSoma Announces New Facility in San Antonio for Diabetes Relief

HOUSTON, TX , April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – AngioSoma, Inc. (OTC: SOAN) announces that Diabetes Relief LLC has licensed a new facility in San Antonio, Texas for its patented treatment, which is about to open. “Diabetes Relief is proud of this facility, which is an important cog in our expansion wheel as we move further west into Texas,” said Dr. Stanley T. Lewis , Chief Medical Officer. “We are anxious to help the thousands of diabetics in the San Antonio area, especially those with foot problems, who may have all but given up hope,” Dr. Lewis added.
According to the National Institutes of Health , foot problems, especially diabetic neuropathy, are common in people with diabetes. See more at www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/foot-problems. Testimonials from Diabetes Relief’s patients (www.diabetesrelief.com) often include amazing improvements in neuropathy and foot ulcers after receiving the patented treatment.
The Diabetes Relief protocol treats insulin resistance and improves insulin sensitivity with an approach that is not satisfied with treating only symptoms but goes to the root cause of metabolic disorder, where conventional treatment has failed. Diabetes Relief now has licensed clinics in Texas , Utah , California , Georgia , Florida , Turkey , Azerbaijan and Lebanon , with others planned in the U.S. and abroad.

AngioSoma Announces Accomplishments of Diabetes Relief

Houston, TX, March 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN) announced today the Company is excited about recent news of accomplishments of Diabetes Relief LLC, whose patented process and procedures treat the root cause of diabetes, instead of just the symptoms, resulting in patient improvement greater than with conventional treatment.

Diabetes Relief Adds Key Milestones for 2019

Diabetes Relief is meeting its goals for new licensed facilities by adding a third Houston captive facility and licensing new centers in Austin, California, and Florida. “Diabetes Relief is poised to improve the lives of millions of diabetics all over the world,” said Scott Hepford, Manager of Diabetes Relief LLC.

Diabetes Relief’s Georgia Facility Exceeds Expectations

Diabetes Relief reports that its licensee in Southeast Georgia has exceeded all hopes for profitability and patient improvements and is looking to expand to Atlanta. “This is what we have envisioned for the Company, and it is exciting to see it happen,” stated Brian Loveridge, MD, Regional Medical Director for Diabetes Relief LLC. “As Diabetes Relief continues to see improvement where conventional treatment has failed, the demand for its patented product are booming,” Dr. Loveridge added. Kerrie Dawson, CEO of DR’s first Georgia expansion, reported that “DR is worth the investment in so many ways for a practice, and we have saved one lady’s leg from amputation!”

Diabetes Relief Licensed Facilities Grow to 11

With the addition of licensed facilities in Jacksonville, Florida, and Thousand Oaks, California, Diabetes Relief’s patented treatment is now offered in 11 facilities and the company is working hard to keep up with the demand for licenses. “We are making plans for a comprehensive peer-reviewed, double-blind study of our amazing process that is changing so many lives once believed hopeless,” said Dr. Stanley Lewis, the Company’s Chief Medical Officer, “while handling the many requests for licenses.”

AngioSoma Announces Acquisition of Diabetes Relief


Houston, TX, Dec. 14, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN) announced today the Company has entered into a partially binding letter of intent to acquire 100% of the equity interests in Diabetes Relief LLC. Diabetes Relief licenses medical facilities for the treatment of metabolic disorder, specializing in diabetes, for the use of patented protocols, processes, and intellectual property. Treatments are individualized to a patient’s condition and metabolic state. Diabetes Relief, through providing thousands of treatments, has seen vast improvements for patients. Clinical trials for FDA approval of Liprostin™, that is intended to treat Peripheral Artery Disease, or PAD, may be facilitated by the acquisition.

Gross revenue of Diabetes Relief for the current year is forecasted to be $2,416,716, for the prior year $1,900,944, and for 2015 was $213,434. Revenue growth is expected to increase substantially.

The following statements are quoted from Diabetes Relief’s patent that was issued May 16, 2017: “It is apparent from the clinical results that the technique has usefulness in treating diabetic implications, including blindness and other ocular manifestations, nerve disease, cardiovascular disease, diabetic nephropathy, and poor wound healing. . . . A need exists for a kit that improves impaired hepatic glucose processing in subjects and produce superior results to those previously obtainable. The present embodiments meet those needs.”

Diabetes Relief’s patented therapy treats the root cause of diabetes, instead of just the symptoms, as conventional treatment has done. Diabetes Relief’s patients improve and they are able to escape the treadmill of treatments that do not work.

AngioSoma Creates New Partnership Opportunity
Peripheral Artery Disease Device Manufacturer Targeted for Joint Venture


HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma (OTC: SOAN), a leading biotechnology research and development company, announces today the execution of a letter of intent to pursue a relationship with Biomedix®.

Biomedix® manufactures a noninvasive device, PADnet, that diagnoses Peripheral Artery Disease (PAD) in patients. Biomedix has over 1,000 PADnet devices under service throughout the United States and can potentially assist in our clinical trials and research, once we determine the scope and breadth of the services needed. We could potentially engage with Biomedix to:

1. Leverage PADnet technology, but using doctors and patients managed by another clinical research partner

2. Leverage PADnet technology through doctors willing to participate, that meets our specifications, such as geography and medical specialty, to assist in the trials.

3. Leverage PADnet technology through identified patients willing to participate, that meets our specifications, such as disease severity and associated risk factors, to assist with the trials

AngioSoma intends to use the PADnet device to select patients for clinical trials and determine the presence and severity of PAD in patients before and after using Liprostin™, its flagship patented pharmaceutical intervention for PAD. Liprostin™ is currently in the approval process of the FDA for marketing. Combining these tightly aligned products will assist doctors in providing the best care possible and give patients peace of mind that interventions are working.

“It’s a natural fit for us,” said Alex Blankenship, President of AngioSoma. “The ability to verify the effectiveness of treatment by testing before and after interventions will enhance our efficacy data, leading to greater visibility for our products going forward.”

AngioSoma, Inc. Announces Grant of Patent for Flagship Drug

HOUSTON, TX, May 14, 2018(GLOBE NEWSWIRE) -- AngioSoma, Inc. (OTC: SOAN) is excited to announce that the U.S. Patent Office has agreed to grant our patent application for our flagship pharmaceutical, Liprostin™ that is intended to treat Peripheral Artery Disease, or PAD.

We are told the market opportunity is significant with 8 million U.S. diagnosed cases of PAD costing $212 - $389 billion annually. PAD costs exceed diabetes, coronary artery disease and cancers. It is reported that 60% to 70% of diabetics contract peripheral artery disease, often resulting in amputation as treatment.

Clinical Trials I, and II a-b-c have shown that Liprostin™ is effective for treating walking pain and circulation. However, the third clinical trial must be successfully completed before Liprostin™ may be commercialized.






SEC Filings

SOAN Twitter
DR Website
DR Twitter
DR Facebook
DR Products
Biomedix Website
Biomedix PADnet Device FAQ
SOAN E Commerce Sites


AngioSoma, Inc.
Alex Blankenship
2500 Wilcrest Drive, Suite 300, Houston, TX 77042
(832) 781-8521

Disclaimer : All of the information posted here ,or Stickied , is based on an individual opinion , and is not to be considered as a recommendation to buy , sell , or hold this stock .

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist